Omidria Side Effects Center

Last updated on RxList: 12/21/2017
Omidria Side Effects Center

Last reviewed on RxList 12/21/2017

Omidria (phenylephrine and ketorolac) Injection is a combination alpha 1-adrenergic receptor agonist and a nonsteroidal anti-inflammatory drug (NSAID) that is added to an ophthalmic irrigation solution used during cataract surgery or intraocular lens replacement and is used for maintaining pupil size by preventing intraoperative miosis and reducing postoperative ocular pain. Common side effects of Omidria include eye inflammation, increased ocular pressure, eye irritation, the feeling of a foreign body being in the eye, sensitivity of eyes to light, sores in the eye, or allergic reactions such as skin rash, swelling of the face, lips, or tongue.

For administration to patients undergoing cataract surgery or intraocular lens replacement, a dose of 4 mL of Omidria is diluted in 500 mL of ophthalmic irrigation solution. Omidria may interact with other drugs. Tell your doctor all medications and supplements you use. During pregnancy, Omidria should only be administered if necessary. Consult your doctor before breastfeeding.

Our Omidria (phenylephrine and ketorolac) Injection Side Effects Drug Center provides a comprehensive view of available drug information on the potential side effects when taking this medication.

This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

SLIDESHOW

Cataracts Causes, Symptoms, Vision Tests, and Surgery See Slideshow
Omidria Professional Information

SIDE EFFECTS

Clinical Studies Experience

Because clinical studies are conducted under widely varying conditions, adverse reaction rates observed in the clinical studies of a drug cannot be directly compared to the rates in the clinical studies of another drug and may not reflect the rates observed in practice.

Table 1 shows frequently reported ocular adverse reactions with an incidence of ≥ 2% of adult patients as seen in the combined clinical trial results from three randomized, placebo-controlled studies [see Clinical Studies].

Table 1: Ocular Adverse Reactions Reported by ≥ 2% of Adult Patients

MedDRA Preferred Term Placebo
(N=462)
Omidria
(N=459)
n (%) n (%)
Ocular Events
  Anterior Chamber Inflammation 102 (22%) 111 (24%)
  Intraocular Pressure Increased 15 (3%) 20 (4%)
  Posterior Capsule Opacification 16 (4%) 18 (4%)
  Eye Irritation 6 (1%) 9 (2%)
  Foreign Body Sensation in Eyes 11 (2%) 8 (2%)

In a safety study that enrolled 72 pediatric patients up to 3 years old, no overall difference in safety was observed between pediatric and adult patients.

Read the entire FDA prescribing information for Omidria (Phenylephrine and Ketorolac Injection)

IMAGES

See Images

© Omidria Patient Information is supplied by Cerner Multum, Inc. and Omidria Consumer information is supplied by First Databank, Inc., used under license and subject to their respective copyrights.

Health Solutions From Our Sponsors